신장 결석 관리 시장 비즈니스 기회, 성장요인, 업계 동향 분석 및 예측(2026-2035년)

The Global Kidney Stone Management Market was valued at USD 2.9 billion in 2025 and is estimated to grow at a CAGR of 4.9% to reach USD 4.8 billion by 2035.

Growth in the kidney stone management market is supported by the increasing global incidence of kidney stone disorders, continuous advancements in treatment technologies, and the steady rise in the aging population. Healthcare providers are witnessing higher patient volumes associated with urinary tract disorders, which is intensifying the demand for reliable diagnostic tools and effective treatment solutions. Medical technology advancements are improving the accuracy of stone detection while also enhancing treatment efficiency and patient safety. Additionally, the shift toward minimally invasive therapeutic approaches is transforming the treatment landscape by offering shorter recovery times and reduced procedural risks. Hospitals and specialty clinics are increasingly adopting modern devices and advanced procedural techniques designed to improve clinical outcomes and optimize patient management. Furthermore, the integration of digital diagnostics and imaging technologies is enabling healthcare professionals to identify kidney stones earlier and plan more precise treatment strategies. Collectively, these developments are driving steady expansion of the kidney stone management market while improving the overall quality of patient care.

Kidney stone management involves the identification, treatment, and long-term control of renal calculi through diagnostic imaging, medical therapy, and minimally invasive or surgical procedures. The primary objective of these interventions is to relieve symptoms, eliminate or break down stones, prevent recurrence, and restore normal urinary system function. Advancements in technologies used for ureteroscopy, laser-based stone fragmentation, extracorporeal shock wave lithotripsy, and percutaneous procedures have significantly enhanced treatment effectiveness. These improvements allow clinicians to perform procedures with greater precision while minimizing complications. The industry is also experiencing rapid growth as healthcare facilities expand their adoption of minimally invasive procedures and ambulatory surgical solutions.

The calcium oxalate segment held 75.7% share in 2025. The segment's leadership is largely attributed to the widespread occurrence of this type of kidney stone and its strong association with metabolic and dietary risk factors. Patients diagnosed with this condition often require repeated monitoring and medical intervention, which contributes to sustained demand for diagnostic and treatment solutions. Because this type of kidney stone frequently recurs, healthcare providers emphasize long-term management strategies that include dietary guidance, medical therapy, and routine monitoring. The high prevalence and recurrent nature of these stones, therefore, continue to support the growth of the calcium oxalate segment within the kidney stone management market.

The treatment segment generated USD 1.7 billion in 2025 and is expected to grow at a CAGR of 5.6% during 2026-2035. The increasing global incidence of kidney stone disease, particularly cases involving recurrence, is driving greater demand for therapeutic interventions. The recurring nature of the condition requires both immediate treatment procedures and continuous patient management, which significantly increases the volume of medical procedures performed worldwide. In addition, improvements in diagnostic technologies are enabling healthcare providers to detect stones at earlier stages and determine their exact location more accurately. Enhanced imaging capabilities support more precise treatment planning and improve clinical outcomes. These developments are increasing physician confidence in modern treatment methods while also contributing to higher procedural efficiency across healthcare facilities.

U.S. Kidney Stone Management Market reached USD 1.2 billion in 2025. The high occurrence of kidney stone disorders across the country continues to create consistent demand for both surgical procedures and preventive care solutions. A considerable portion of patients experience recurrent stone formation, which requires ongoing monitoring and multiple treatment interventions. This pattern contributes to sustained market activity and increased demand for advanced medical technologies. The United States also benefits from a well-developed healthcare infrastructure that includes hospitals and ambulatory surgical centers equipped with advanced lithotripsy systems, ureteroscopy devices, and laser-based treatment technologies. Access to sophisticated diagnostic imaging systems supports earlier disease detection and improved treatment planning. As healthcare providers continue to prioritize minimally invasive techniques, treatment efficiency and patient throughput are steadily improving across the healthcare system.

Several leading companies participate in the Global Kidney Stone Management Market, including Allengers, Becton, Dickinson and Company, Boston Scientific, Coloplast, COOK MEDICAL, DirexGroup, Dornier MedTech, ELMED Medical Systems, EMS ELECTRO MEDICAL SYSTEMS, KARL STORZ, MEDISPEC, OLYMPUS, PolyDiagnost, Richard Wolf, and SIEMENS Healthineers. Companies operating in the Global Kidney Stone Management Market are implementing a range of strategic initiatives to strengthen their market presence and expand their global footprint. Leading manufacturers are heavily investing in research and development to introduce technologically advanced treatment systems that enhance procedural precision and patient outcomes. Many firms are also focusing on product innovation by integrating improved imaging capabilities, digital connectivity, and advanced laser technologies into their medical devices. Strategic collaborations with healthcare institutions and technology providers are helping companies accelerate product development and broaden clinical adoption. Additionally, expansion into emerging healthcare markets through partnerships and distribution agreements is allowing companies to increase accessibility to advanced treatment solutions.

Table of Contents

Chapter 1 Research Methodology

• 1.1 Research approach
• 1.2 Quality commitments
  • 1.2.1 GMI AI policy & data integrity commitment
    • 1.2.1.1 Source consistency protocol
• 1.3 Research trail & confidence scoring
  • 1.3.1 Research trail components
  • 1.3.2 Scoring components
• 1.4 Data collection
  • 1.4.1 Partial list of primary sources
• 1.5 Data mining sources
  • 1.5.1 Paid sources
    • 1.5.1.1 Sources, by region
• 1.6 Base estimates and calculations
  • 1.6.1 Base year calculation for any one approach
• 1.7 Forecast model
  • 1.7.1 Quantified market impact analysis
    • 1.7.1.1 Mathematical impact of growth parameters on forecast
• 1.8 Research transparency addendum
  • 1.8.1 Source attribution framework
  • 1.8.2 Quality assurance metrics
  • 1.8.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Stone type trends
  • 2.2.3 Category trends
  • 2.2.4 End use trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence and recurrence rate of kidney stones
    • 3.2.1.2 Technological advancements in minimally invasive treatments
    • 3.2.1.3 Favourable reimbursement for lithotripsy procedures
    • 3.2.1.4 Rising awareness regarding overall kidney health
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of advanced treatment devices
    • 3.2.2.2 Potential long-term adverse effects of lithotripsy
  • 3.2.3 Market opportunities
    • 3.2.3.1 Expansion in emerging markets
    • 3.2.3.2 Growth of telemedicine and remote patient monitoring
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Technology landscape
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Reimbursement scenario
• 3.7 Future market trends
• 3.8 Porter's analysis
• 3.9 PESTEL analysis
• 3.10 Value chain analysis
• 3.11 Customer insights
• 3.12 Start-up scenarios
• 3.13 Gap analysis
• 3.14 Impact of AI and generative AI on the market

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
  • 4.3.1 Global
  • 4.3.2 North America
  • 4.3.3 Europe
  • 4.3.4 Asia Pacific
• 4.4 Competitive positioning matrix
• 4.5 Competitive analysis of major market players
• 4.6 Key developments
  • 4.6.1 Mergers & acquisitions
  • 4.6.2 Partnerships & collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Stone Type, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Calcium oxalate
• 5.3 Struvite
• 5.4 Uric acid
• 5.5 Calcium phosphate
• 5.6 Cysteine

Chapter 6 Market Estimates and Forecast, By Category, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Treatment
  • 6.2.1 Extracorporeal shock wave lithotripsy (ESWL)
  • 6.2.2 Ureteroscopy
  • 6.2.3 Percutaneous nephrolithotomy (PCNL)
  • 6.2.4 Other treatments
• 6.3 Diagnostics
  • 6.3.1 Computed tomography
  • 6.3.2 Ultrasound
  • 6.3.3 Abdominal x-ray
  • 6.3.4 Intravenous pyelography
  • 6.3.5 Abdominal MRI
  • 6.3.6 Other diagnostics

Chapter 7 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Specialty clinics
• 7.4 Ambulatory surgical centers
• 7.5 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Allengers
• 9.2 Becton, Dickinson and Company
• 9.3 Boston Scientific
• 9.4 Coloplast
• 9.5 COOK MEDICAL
• 9.6 DirexGroup
• 9.7 Dornier MedTech
• 9.8 ELMED Medical Systems
• 9.9 EMS ELECTRO MEDICAL SYSTEMS
• 9.10 KARL STORZ
• 9.11 MEDISPEC
• 9.12 OLYMPUS
• 9.13 PolyDiagnost
• 9.14 Richard Wolf
• 9.15 SIEMENS Healthineers